Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.

Scientific reports - 12 Dec 2025

Giraud Emilie, Piorkowski Géraldine, Driouich Jean-Sélim, Bernadin Ornéllie, Durand Cyrielle, Gilles Magali, Amaral Rayane, van der Werf Sylvie, de Lamballerie Xavier, Agou Fabrice, Nougairède Antoine, Touret Franck

Abstract excerpt

In late 2023, the BA.2.86 and EG.5.1 SARS-CoV-2 variants co-circulated globally, raising concerns about enhanced immune evasion and altered replicative capacity. In this study, we assessed their virological characteristics using live viruses. We evaluated sensitivity to therapeutic monoclonal antibodies and antivirals targeting NSP5 and NSP12, and performed direct competition assays. BA.2.86 displayed a complete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chlorocebus aethiops

Share to COVID-19

Share to Cricetinae

Share to SARS-CoV-2

Share to Vero Cells

Share to Virus Replication

Source

Open in PubMed Open full text

Identifiers

PMID: 41387746
DOI: 10.1038/s41598-025-27481-0
PMCID: PMC12700878

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.PMID 41387746Read ↗

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variantSemantic proximity Read ↗

Virological characteristics of the SARS-CoV-2 BA.2.86 variant.Semantic proximity Read ↗

Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasionSemantic proximity Read ↗

Virological characteristics of the SARS-CoV-2 BA.2.86 variantSemantic proximity Read ↗

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concernSemantic proximity Read ↗

Profound neutralization evasion and augmented host cell entry are hallmarks of the fast-spreading SARS-CoV-2 lineage XBB.1.5Semantic proximity Read ↗

SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of ConcernSemantic proximity Read ↗

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2Semantic proximity Read ↗

Rapid spread of the SARS-CoV-2 JN.1 lineage is associated with increased neutralization evasionSemantic proximity Read ↗

Long-term passaging of replication competent pseudo-typed SARS-CoV-2 reveals the antiviral breadth of monoclonal and bispecific antibody cocktailsSemantic proximity Read ↗

Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal seraSemantic proximity Read ↗

Comparative analysis of SARS‐CoV‐2 Omicron BA.2.12.1 and BA.5.2 variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.